{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"26"}]}],"title":"<=450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"13"}]}],"title":">450 to <=480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":">480 to <=500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}],"title":">500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"14"}]}],"title":">30 to <=60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"}]}],"title":">60 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"45"}],"units":"Participants"}],"description":"Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.","groups":[{"description":"Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until maximum MTD or maximum MED achieved.","id":"OG000","title":"Phase 1: FT-2102 (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD and BID in 28-day cycles at the differ-ent dose levels (150 mg and ≤ 300 mg) until MTD or MED achieved.","id":"OG001","title":"Phase 1: Total FT-2102 (Single Agent)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG002","title":"Phase 1: FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 150 mg and ≤ 300 mg and azacitidine administered at the dose of 75 mg/m\\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.","id":"OG003","title":"Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SAS. Here, N=Number of participants with available data. Since 150mg BID has been established as MTD, analysis was directed towards emphasizing findings that are most relevant for determining safe and effective treatment strategy. Accordingly, data for other dose levels (100mg QD, 150mg QD, and 300mg QD) were combined as prespecified in SAP.","reportingStatus":"POSTED","timeFrame":"Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)","title":"Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)","type":"PRIMARY","unitOfMeasure":"Participants"}